NTT and Microsoft Form a Strategic Alliance to Enable New Digital Solutions
10.12.2019 16:00:00 EET | Business Wire | Press release
NTT Corporation (NTT) and Microsoft Corp. today announced a multi-year strategic alliance aimed at delivering secure and reliable solutions that help enterprise customers accelerate their digital transformations. The alliance will bring together NTT’s best-in-class ICT infrastructure, managed services and cybersecurity expertise, with Microsoft’s trusted cloud platform and AI technologies. Key initiatives of the alliance include the creation of a Global Digital Fabric, development of digital enterprise solutions built on Microsoft Azure, and co-innovation of next-generation technologies in the area of all-photonics network and digital twin computing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191210005480/en/
Satya Nadella, CEO, Microsoft (left), Jun Sawada, CEO, NTT (right) (Photo: Business Wire)
As one of the world’s largest global technology and business solution organizations, NTT provides integrated services that include digital business consulting and managed services for cybersecurity, applications, cloud, datacenters and global networks in over 190 countries and regions. As part of the strategic alliance, NTT has chosen Microsoft Azure as its preferred cloud platform for modernizing its global IT infrastructure and customer solutions in the areas of advanced analytics for cybersecurity threat intelligence and the hybrid-IT management platform.
“NTT is committed to helping enterprises realize their digital transformation initiatives to help create a smarter world. We believe that the combination of the Microsoft Azure platform along with NTT’s connected infrastructure and service delivery capabilities will accelerate these efforts. Additionally, the companies will collaborate on IOWN, including areas such as all-photonics network and digital twin computing,” said Jun Sawada, President and CEO of NTT.
“Our strategic alliance combines NTT’s global infrastructure and services expertise with the power of Azure,” said Satya Nadella, CEO, Microsoft. “Together, we will build new solutions spanning AI, cybersecurity and hybrid cloud, as we work to help enterprise customers everywhere accelerate their digital transformation.”
Key initiatives of the alliance include:
1. Formation of a Global Digital Fabric
Global Digital Fabric is a combination of Microsoft Cloud and NTT’s globally connected ICT infrastructure. It brings together the strengths of the two companies in the areas of productivity solutions, public cloud, global datacenter and network infrastructure. The Global Digital Fabric aims to create a highly sustainable, secure and robust environment for enterprises to accelerate their digital ambitions around the world.
2. Development of digital enterprise solutions
The alliance also covers the development of digital solutions built on Microsoft Azure to empower enterprises to accelerate their digital transformation and to operate more securely from the enterprise to the edge to the cloud. Key initiatives include advanced analytics for cybersecurity threat intelligence, social robotics with relational AI for digital companions, digital workplace solutions, as well as knowledge discovery and management.
3. Co-innovation of next-generation technologies
The alliance will also explore research and development of all-photonics network and digital twin computing as part of NTT’s Innovative Optical and Wireless Network (IOWN) concept. The goal is to provide a more natural interaction between people, nature and technology, and to support sustainable growth with an optical-based networking and information processing platform of the future.
Furthermore, NTT and Microsoft are committed to harnessing the power of technology for a more sustainable future. The companies intend to work together to invest in innovative projects that leverage technology to build on NTT’s sustainability initiatives and Microsoft’s AI for Earth grants.
“NTT and Microsoft have a long history of collaboration, and this strategic alliance will further deepen our partnership. We share the same vision of empowering enterprises and society with intelligent and secure technologies for a better and more sustainable future,” said Jun Sawada, President and CEO of NTT.
About NTT
NTT is a global technology and business solutions provider helping clients accelerate growth and innovate digital business models.
We provide digital business consulting, technology and managed services for cybersecurity, applications, workplace, cloud, data center and networks – all supported by our deep industry expertise and innovation.
As a top-five global IT services provider, our diverse teams deliver services in 190+ countries and regions. We serve 85% of the Fortune Global 100 companies and thousands of other clients and communities.
With a 120-year heritage of service and social responsibility we advocate and act for our clients and a sustainable world.
For more information on NTT, visit www.global.ntt.
About Microsoft
Microsoft (Nasdaq “MSFT” @microsoft) enables digital transformation for the era of an intelligent cloud and an intelligent edge. Its mission is to empower every person and every organization on the planet to achieve more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005480/en/
Contact information
NTT
Public Relations
Tomoka Ito
ntt-cnr-ml@hco.ntt.co.jp
Microsoft Media Relations
WE Communications for Microsoft
(425) 638-7777
rrt@we-worldwide.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom